Clinical randomized comparative trial of DICE regimen and CHOP regimen in treating intermediate and high grade non-Hodgkin’s lymphoma

Objective: To compare efficacies and safeties of DICE and CHOP regimens in treating intermediate and high grade non-Hodgkin's lymphoma (NHL), and indicate the standard treatment for it. Methods: A total of 74 patients with moder- ately or highly malignant NHL, verified by pathology or histology, were randomized into the trial group (37 patients treated with DICE regimen) and the control group (37 patients treated with CHOP regimen). Survival rate was analyzed by Kaplan-Meier method. Chi-square test was performed between groups. Results: The complete response rate, partial response rate, and response rate were significantly higher in DICE group than in CHOP group (40.5% vs. 29.7%, 37.8% vs. 27.0%, and 78.3% vs. 56.7%, respectively, P < 0.05). The 1-, 3-, and 5-year survival rates were significantly higher in DICE group than in CHOP group (89.2% vs. 81.2%, 76.0% vs. 52.6%%, and 46.7% vs. 36.4%, respectively, P < 0.05). The major side effects, appeared with no differences (P > 0.05) in incidences between the two groups, were leukopenia, thrombocytopenia, and nausea. There were only three episodes of clinical cystitis or gross haematuria in DICE regimen. Conclusion: The results showed higher efficacy of DICE regimen over CHOP regimen. DICE regimen may prolong the survival time of patients with moderately and highly malignant NHL.

Comparison of Immune Effect of Four Commercial Marek's Disease Vaccines in Wenchang Chicken

Marek＇s disease（MD） is a lymphoproliferative disease of domestic chickens caused by a highly infectious,oncogenic alpha-herpesvirus known as Marek＇s disease virus（MDV）.The aim of this study was to compare the efficacy of four commercial MDV vaccines in Wenchang chicken.The 1-day old Wenchang chickens tested were injected with one of four different vaccines or not unvaccinated as control;five days later,they were then challenged by virulent MDV strain MD5.The results showed that,in comparison with HVT vaccines,the CVI988 vaccine gave the immunized chickens more potent immunities against challenges of MDV strain MD5.

Macromineral requirements of Dorper×thin-tailed Han crossbred female lambs

A comparative slaughter trial was conducted to determine the net mineral requirements for maintenance and growth of Dorper crossbred female lambs raised from 20 to 35 kg of body weight（BW）.Thirty-five Dorper×thin-tailed Han crossbred female lambs of（20.3±1.14） kg BW were used： 7 lambs were randomly chosen and slaughtered at the beginning of the experiment as the baseline group for measuring the initial body composition; another 7 lambs were randomly chosen and offered a pelleted mixed diet ad libitum and slaughtered at（27.0±0.73） kg BW; the remaining 21 lambs were randomly divided into 3 groups of 7 animals each and subjected to the same diet either ad l ibitum or at 70 or 40% of ad libitum intake.The 21 lambs were fed in 7 slaughter groups, with each group consisting of one lamb from each treatment（ad libitum, 70 or 40% of ad libitum intake）.The 3 groups were slaughtered when the sheep fed ad libitum attained（33.8±0.52） kg of BW.The body composition of five minerals（Ca, P, Na, K, and Mg） was determined.The net mineral requirements for maintenance were 35.01, 25.18, 9.30, 31.35, and 2.03 mg kg–1 empty BW（EBW） for Ca, P, Na, K, and Mg, respectively, and the net growth requirement per kg of EBW gain ranged from 9.73 to 8.87 g of Ca, 5.83 to 5.27 g of P, 1.73 to 1.63 g of Na, 3.73 to 4.08 g of K, and 0.26 to 0.25 g of Mg for Dorper crossbred lambs in China, respectively.The estimates of mineral requirements with Dorper crossbred lambs in the current study were not consistent with the recommendations from previous studies.

Traumatic brain injury： Changing concepts and approaches

Traumatic brain injury （TBI） represents a huge global medical and public health problem across all ages and in all populations. In this review, we discussed the changing concepts and approaches. Globally, the incidence is increasing and in high income countries epidemiologic patterns are changing with conse- quences for prevention campaigns. TBI should not be viewed as an event, but as a progressive and chronic disease with lifetime consequences. In the clinical field, precision approaches to treatment are being developed, which require more accurate disease phenotyping. Recent advances in genomics, neuroimaging and biomarker development offer great opportunities to develop improved phenotyping and better disease characterization. In clinical research, randomized controlled clinical trials are being complemented by large data collections in broad TBI populations in comparative effectiveness designs. Global collaborations are being developed among funding agencies, research organizations and re- searchers. Only by combining efforts and collaboration will we be able to advance the field by providing long-needed evidence to SUnoort practice recommendatians and to improve treatment